Updates in AxSpA from EULAR 2025 include 3-year data for bimekizumab, definition of difficult-to-manage subgroups, ...

Rheumatoid arthritis and spondyloarthritis are long-lasting inflammatory diseases that gradually wear down joints. While ...

Ivarmacitinib, a highly selective Janus kinase 1 inhibitor, tops placebo in managing signs and symptoms of active ankylosing ...

Expansion of treatment options for axial spondyloarthritis (axSpA) has brought attention to documented delays in diagnosis, which is estimated to be an average of 6.7 years worldwide ...

Inspired by feedback from the hidradenitis suppurativa (HS) community, the campaign aims to raise awareness of BIMZELX and features a broad range of ...

People with back pain face some uncertainty in diagnosis that is unsettling to patients and physicians alike. But once a diagnosis of axial spondyloarthritis (axSpA) is made, concerns often shift ...

The pharma began its outreach to the HS community well before securing Bimzelx’s approval in the indication. In the spring of ...

The study, published Feb. 13 in Gut Microbes, also demonstrated that the gut microbiota of people with Crohn's and axial spondyloarthritis ... affects more than half a million Americans and causes ...

The GCAptAIN study did not meet its primary endpoint of sustained remission at Week 52 in adults with newly diagnosed or relapsing GCA1 ...

Symptoms that signal this inflammation—like fatigue ... In men, this may more frequently crop up as spondyloarthritis, a progressive disease that primarily affects the spine. That’s a big reason why ...

AS can also involve gastrointestinal symptoms and, in some cases, chronic inflammatory bowel diseases (IBD), such as Crohn’s disease or ulcerative colitis , may be present.